quinolines were synthesized and evaluated as in vitro inhibitors of Mycobacterium tuberculosis (M. tuberculosis) growth. Structure-activity relationship (SAR) studies leaded to potent antitubercular agents, with minimum inhibitory concentration (MIC) values as low as 0.3 μM against M. tuberculosis H37Rv reference strain. Furthermore, the lead compounds were active against multidrug-resistant strains
使用经典的分子简化方法,合成了36种
喹啉系列,并作为结核分枝杆菌(M. tuberculosis)生长的体外
抑制剂进行了评估。结构-活性关系(
SAR)研究导致了有效的抗结核药,针对结核分枝杆菌H37Rv参考菌株的最低抑菌浓度(MIC)值低至0.3μM。此外,先导化合物对多药耐药菌株具有活性,而与某些一线和二线药物没有交叉耐药性。对分子进行抗qcrB
基因中单个突变的自发突变菌株的测试(T313A),表明合成的
喹啉靶向细胞色素bc1复合物。此外,前体化合物对HepG2和Vero细胞没有明显的毒性,并且在人肝S9组分中显示出中等的消除率。最后,在结核感染的巨噬细胞模型中,选定的结构抑制了结核分枝杆菌的生长。综合来看,这些数据表明这类化合物可能为抗结核药物的未来发展提供候选。